Phillips making waves as digital healthcare provider

Phillips is making waves in combining healthcare and digital communications, in order to provide patients with quality and tailored solutions.

Recent months have seen Phillips chalk up several impressive launches and accolades as it moves further into providing digital solutions for healthcare. Earlier this month saw the company open its first co-creation centre to support care organisations with the transformation to new models for connected health care enabled by digital technologies.

Earlier still was the news that the company had introduced personal health programmes, which included a combination of connected health measurement devices, app-based health programmes and cloud based data analysis. This is evidence of the innumerable possibilities afforded by digital technology, especially in conjuncture with healthcare. But most recently, the company has partnered up with Netherlands-based Radboud university medical center to introduce a diabetes prototype app with integrated online community to empower patients and enhance continuity of care.

The prototype enables people living with their diabetes and their health care provides make more confident care decisions while managing the complexity of diabetes self-care. In its first phase, the solution both originations are developing will focus primarily on patients living with type 1 diabetes.

The system, consisting on a mobile patient app and online community, is the first to collect and connect data from electronic medical records, multiple personal health devices – including wireless glucose meters and activity monitors – and patient self-reported data.

Via a smartphone of tablet device, the app gives patients continuous access to important parameters such as blood glucose levels, insulin use, and nutrition and provides coaching guidance at home and on the go. The secure online community is where enrolled patients and healthcare professionals can interact via private messaging or shared posts within a healthcare organisation’s clinical guidelines. In this way, patients can get feedback from their care team using combined data and can easily share experiences with fellow patients, clinicians and caregivers.

Photo credit: Phillips


A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...

Enrolment opens for 4D Pharma’s phase II study of live biotherapeutic in COVID-19

4D Pharma, the listed Leeds-based pharma company developing Live Biotherapeutics, has announced that its Phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients...

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Related news

CDMOs team up to simplify processes, optimise time-to-market

CDMOs Vetter and Rentschler Biopharma are collaborating to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain. With drug development...

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...